0A9B Stock Overview
Provides clinical laboratory and medical diagnostic services for insurance companies, hospitals, pharmacies, national health organizations, practicing doctors, clinics, patients, governments, and corporations primarily in Europe. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
SYNLAB AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €11.09 |
52 Week High | €12.43 |
52 Week Low | €9.88 |
Beta | 0.89 |
11 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | 11.48% |
33 Year Change | -47.96% |
5 Year Change | n/a |
Change since IPO | -42.56% |
Recent News & Updates
Recent updates
Shareholder Returns
0A9B | GB Healthcare | GB Market | |
---|---|---|---|
7D | 0% | -2.5% | 0.8% |
1Y | 11.5% | -23.5% | 6.6% |
Return vs Industry: 0A9B exceeded the UK Healthcare industry which returned -13.3% over the past year.
Return vs Market: 0A9B matched the UK Market which returned 11.7% over the past year.
Price Volatility
0A9B volatility | |
---|---|
0A9B Average Weekly Movement | n/a |
Healthcare Industry Average Movement | 6.4% |
Market Average Movement | 4.7% |
10% most volatile stocks in GB Market | 10.3% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A9B's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0A9B's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 27,000 | Mathieu Floreani | www.synlab.com |
SYNLAB AG provides clinical laboratory and medical diagnostic services for insurance companies, hospitals, pharmacies, national health organizations, practicing doctors, clinics, patients, governments, and corporations primarily in Europe. The company offers medical and veterinary diagnostics services. SYNLAB AG was founded in 1998 and is headquartered in Munich, Germany.
SYNLAB AG Fundamentals Summary
0A9B fundamental statistics | |
---|---|
Market cap | €2.42b |
Earnings (TTM) | €89.35m |
Revenue (TTM) | €2.62b |
27.1x
P/E Ratio0.9x
P/S RatioIs 0A9B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0A9B income statement (TTM) | |
---|---|
Revenue | €2.62b |
Cost of Revenue | €604.92m |
Gross Profit | €2.01b |
Other Expenses | €1.92b |
Earnings | €89.35m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Nov 07, 2024
Earnings per share (EPS) | 0.41 |
Gross Margin | 76.87% |
Net Profit Margin | 3.42% |
Debt/Equity Ratio | 39.0% |
How did 0A9B perform over the long term?
See historical performance and comparison